RNF216 as a Promising Biomarker for Prognosis, Immunotherapy, and Chemotherapy in LIHC: A Comprehensive Pan-Cancer Analysis and Experimental Validation
Journal of Cancer · 30.01.2026 · 17 (3) · 483-506
DOI: 10.7150/jca.125407 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer, erschienen am 30.01.2026. Verfasst von Ke Du und 9 weiteren Autor:innen. Beteiligte Einrichtung: National and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'…. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Zitieren
APA
Du, K., Liang, X., Qin, B., Liu, Z., Liu, N., Li, P., Wang, Q., Qi, Y., Shi, E., & Li, K. (2026). RNF216 as a Promising Biomarker for Prognosis, Immunotherapy, and Chemotherapy in LIHC: A Comprehensive Pan-Cancer Analysis and Experimental Validation. Journal of Cancer, 17(3), 483-506. https://doi.org/10.7150/jca.125407
Vancouver
Du K, Liang X, Qin B, Liu Z, Liu N, Li P, et al. RNF216 as a Promising Biomarker for Prognosis, Immunotherapy, and Chemotherapy in LIHC: A Comprehensive Pan-Cancer Analysis and Experimental Validation. Journal of Cancer. 2026;17(3):483-506. doi:10.7150/jca.125407
BibTeX
@article{Du2026,
author = {Du, Ke and Liang, Xiao and Qin, Bowen and Liu, Zitao and Liu, Nanbin and Li, Pincheng and Wang, Qian and Qi, Yajie and Shi, Enze and Li, Kun},
title = {RNF216 as a Promising Biomarker for Prognosis, Immunotherapy, and Chemotherapy in LIHC: A Comprehensive Pan-Cancer Analysis and Experimental Validation},
journal = {Journal of Cancer},
year = {2026},
volume = {17},
number = {3},
pages = {483--506},
doi = {10.7150/jca.125407}
}
EUVIMED